# A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia Patients

> **NCT07644351** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 37 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07644351
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-16
- **Primary completion:** 2025-09-17
- **Final completion:** 2025-09-17
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2026-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07644351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07644351, "A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia Patients". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07644351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*